$INCY

Stein Steven H sold $3.2M of INCY

Stein Steven H (CMO & Head of Late-Stage Dev.) sold 28,237 shares of INCYTE CORP (INCY) at $113.05 ($3.19M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Stein Steven H
Published Jul 16, 2026, 8:07 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 16, 2026, 8:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$INCY
Neutral
high confidence
Mentioned
$INCY
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INCYNeutralLow
01

Why it matters

The only new information is the disclosed sale size, price, and post-transaction holdings; it does not introduce new company fundamentals.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the 10b5-1 structure limits interpretive value.

03

What to watch

The filing does not disclose any change in company guidance, trial results, or business performance; traders should avoid extrapolating fundamentals from a single planned sale.

Relevance 5/10Novelty 3/10Timing: today’s SEC Form 4 filing (filed 2026-07-16)

Background

The article is an SEC Form 4 insider transaction for Incyte, reported by an officer (CMO and Head of Late-Stage Development).

Company-level read

Ticker impact

$INCYNeutralHigh confidence
Context

Incyte Form 4 shows officer Stein Steven H sold 28,237 shares at $113.05 on 2026-07-15 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a routine open-market sale by an officer, explicitly under a pre-arranged Rule 10b5-1 plan, with no new operational, financial, or regulatory information disclosed.

Market effects

Minimal; insider-sale disclosures rarely reset sector expectations without accompanying company-specific catalysts.

None.

None.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • INCY

    Incyte Corp, the subject of the Form 4 insider transaction.

  • Stein Steven H

    CMO and Head of Late-Stage Development who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INCYHigh

Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks

Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (INCY) and Biogen (BIIB) as top stock picks, focusing on healthcare over AI. Incyte's stock is up 22% this year, with strong earnings and a growing drug pipeline. The company reported 38% revenue growth and raised its 2026 sales guidance. Risks include Jakafi's patent expiration and competition for Opzelura.

$INCYHighAI 9/10

Incyte Corporation (INCY) vs. Revolution Medicines (RVMD): Which Biotech Stock Offers the Better KRAS Opportunity?

Incyte (INCY) and Revolution Medicines (RVMD) are competing in the KRAS inhibitor market. RBC noted INCY's upcoming ESMO data for its KRAS G12D inhibitor, while Bernstein raised RVMD's price target. RVMD received FDA approval for Rasonque. INCY reported Q2 2026 revenue of $1.67B, while RVMD had no product revenue but $3.9B in cash. Institutional investors favor RVMD, with notable holdings by Farallon Capital and Baker Bros. Advisors.

$INCYHighAI 8/10

How Q2 Beat, Opzelura Demand and Niktimvo Approval At Incyte (INCY) Has Changed Its Investment Story

Incyte (INCY) reported Q2 2026 earnings and revenue above expectations, driven by strong demand for Jakafi and Opzelura. The company raised its 2026 net product revenue guidance and received FDA approval for Niktimvo, adding a new therapy to its portfolio. Analysts project varying revenue and earnings estimates for 2029, with the company targeting $5.8 billion in revenue and $1.1 billion in earnings, while the lowest estimates predict $5.4 billion in revenue and $1.2 billion in earnings.

$INCYHighAI 8/10

Incyte Stock: Is Wall Street Bullish or Bearish?

Incyte (INCY) raised its 2026 revenue forecast to $5.13B-$5.26B after a CMS settlement. Q2 2026 net sales rose 40% to $1.49B, and adjusted EPS was $3.09, beating estimates. Analysts expect FY 2026 EPS to decrease 52.7% YoY to $2.64. The stock has a 'Moderate Buy' consensus rating, with a mean price target of $127.09.